- Home
- LSF vs COEP Comparison
LSF vs COEP Comparison
Compare LSF & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | COEP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 72.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSF | COEP |
|---|---|---|
| Price | $2.62 | $12.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 43.2K | 32.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,295,137.00 | N/A |
| Revenue This Year | $15.87 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.50 | N/A |
| 52 Week Low | $1.98 | $6.32 |
| 52 Week High | $7.94 | $21.41 |
Technical Indicators
Market Signals| Indicator | LSF | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 38.35 | 48.81 |
| Support Level | $2.46 | $10.83 |
| Resistance Level | $2.76 | $13.12 |
| Average True Range (ATR) | 0.19 | 0.83 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 26.11 | 52.61 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.